VOR Vor Bio, Inc.
Vor Bio, Inc. (VOR) is expected to report earnings on November 10, 2026, before the market open. The consensus earnings estimate is a loss of $0.85 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -0.3% since its last earnings release on August 11, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Vor Bio, Inc.
Vor Biopharma Inc. is a cell therapy company pioneering engineered hematopoietic stem cell therapies combined with targeted therapies for the treatment of cancer. Vor Biopharma Inc. is based in CAMBRIDGE, Mass.
Sector
Healthcare
Industry
Biotechnology